Since the launch of the partnership in February 2024, Pfizer has received applications from over 200 start-ups across the ...

Patrick Ruane had a "compulsive and obsessive" mindset about the vaccines, he said, and often posted messages while "blind drunk".

Yet, despite recently beating analysts' expectations for the third quarter on both the top and bottom lines -- while also raising full-year guidance -- Zoetis' share price has slid 12% in the last ...

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

Pfizer's stock underperforms the S&P 500, facing patent expirations and competition, yet offers a 6.3% forward dividend yield. Despite a positive Q3 earnings surprise, profitability remains weaker ...

PPM America Capital Partners is pleased to announce the hiring of Bhumika Gashti, CFA, as Senior Managing Director, Investor Relations.

India should focus on enhancing local vaccine manufacturing and research for better control over safety, according to GTRI. They also suggest investigating adverse health events post-vaccination to ...

Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.

Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer and UCB. The departures coincided with ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.